Bellevue Group’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.1M | Sell |
155,571
-83,109
| -35% | -$7.63M | 0.33% | 57 |
|
|
2025
Q4 | $21.5M | Sell |
238,680
-6,522
| -3% | -$618K | 0.41% | 49 |
|
|
2025
Q3 | $24.2M | Sell |
245,202
-22,514
| -8% | -$2.23M | 0.5% | 43 |
|
|
2025
Q2 | $24.4M | Sell |
267,716
-23,630
| -8% | -$2.28M | 0.54% | 48 |
|
|
2025
Q1 | $33M | Sell |
291,346
-2,275
| -0.8% | -$243K | 0.74% | 32 |
|
|
2024
Q4 | $31M | Sell |
293,621
-139,184
| -32% | -$14.9M | 0.6% | 41 |
|
|
2024
Q3 | $46.7M | Sell |
432,805
-16,276
| -4% | -$1.78M | 0.76% | 34 |
|
|
2024
Q2 | $48.7M | Buy |
449,081
+166,864
| +59% | +$19.7M | 0.79% | 30 |
|
|
2024
Q1 | $37.2M | Buy |
282,217
+1,129
| +0.4% | +$141K | 0.57% | 58 |
|
|
2023
Q4 | $34.2M | Sell |
281,088
-3,800
| -1% | -$424K | 0.52% | 56 |
|
|
2023
Q3 | $32M | Buy |
284,888
+53
| +0% | +$6.73K | 0.52% | 54 |
|
|
2023
Q2 | $41.5M | Buy |
284,835
+19,565
| +7% | +$2.66M | 0.59% | 55 |
|
|
2023
Q1 | $34.3M | Sell |
265,270
-1,026
| -0.4% | -$129K | 0.5% | 59 |
|
|
2022
Q4 | $34M | Buy |
266,296
+1,026
| +0.4% | +$119K | 0.45% | 63 |
|
|
2022
Q3 | $27.7M | Sell |
265,270
-817
| -0.3% | -$89.7K | 0.4% | 66 |
|
|
2022
Q2 | $28M | Sell |
266,087
-4,647
| -2% | -$551K | 0.4% | 68 |
|
|
2022
Q1 | $34.6M | Sell |
270,734
-8,592
| -3% | -$1.04M | 0.4% | 76 |
|
|
2021
Q4 | $34.5M | Sell |
279,326
-9,158
| -3% | -$1.2M | 0.36% | 81 |
|
|
2021
Q3 | $41M | Hold |
288,484
| – | – | 0.42% | 75 |
|
|
2021
Q2 | $45M | Hold |
288,484
| – | – | 0.44% | 71 |
|
|
2021
Q1 | $44.8M | Buy |
288,484
+36,380
| +14% | +$5.64M | 0.47% | 69 |
|
|
2020
Q4 | $37.7M | Buy |
252,104
+19,592
| +8% | +$2.77M | 0.43% | 67 |
|
|
2020
Q3 | $30.7M | Sell |
232,512
-1,821
| -0.8% | -$238K | 0.42% | 65 |
|
|
2020
Q2 | $27.2M | Buy |
234,333
+126,356
| +117% | +$14.6M | 0.38% | 63 |
|
|
2020
Q1 | $10.6M | Sell |
107,977
-113,506
| -51% | -$14.9M | 0.21% | 86 |
|
|
2019
Q4 | $32.2M | Buy |
221,483
+72,779
| +49% | +$10M | 0.51% | 50 |
|
|
2019
Q3 | $19.8M | Buy |
148,704
+44,469
| +43% | +$5.74M | 0.37% | 60 |
|
|
2019
Q2 | $11.9M | Sell |
104,235
-14,165
| -12% | -$1.66M | 0.2% | 76 |
|
|
2019
Q1 | $14.7M | Buy |
118,400
+23,533
| +25% | +$2.67M | 0.81% | 39 |
|
|
2018
Q4 | $9.55M | Hold |
94,867
| – | – | 0.63% | 46 |
|
|
2018
Q3 | $12.1M | Buy |
94,867
+21,324
| +29% | +$2.54M | 0.77% | 44 |
|
|
2018
Q2 | $7.96M | Sell |
73,543
-11,947
| -14% | -$1.3M | 0.68% | 49 |
|
|
2018
Q1 | $9.05M | Hold |
85,490
| – | – | 0.9% | 43 |
|
|
2017
Q4 | $10M | Sell |
85,490
-10,300
| -11% | -$1.16M | 1.05% | 38 |
|
|
2017
Q3 | $10.9M | Buy |
95,790
+5,150
| +6% | +$594K | 1.14% | 31 |
|
|
2017
Q2 | $11.3M | Hold |
90,640
| – | – | 1.34% | 28 |
|
|
2017
Q1 | $10.7M | Sell |
90,640
-15,450
| -15% | -$1.75M | 1.43% | 27 |
|
|
2016
Q4 | $10.6M | Buy |
106,090
+23,690
| +29% | +$2.54M | 2.18% | 15 |
|
|
2016
Q3 | $10.4M | Sell |
82,400
-6,386
| -7% | -$789K | 1.88% | 13 |
|
|
2016
Q2 | $10.4M | Hold |
88,786
| – | – | 1.95% | 15 |
|
|
2016
Q1 | $9.19M | Buy |
+88,786
| New | +$8.59M | 1.67% | 16 |
|
Other funds holding ZBH
VCM
VPM
Bellevue Group's ZBH Position: Q1 2026 in Review
Bellevue Group reduced its Zimmer Biomet (ZBH) stake by 35% in Q1 2026, selling an estimated $7.63M and leaving 155,571 shares worth $14.1M. The position accounts for 0.33% of the portfolio, ranked #57.
Bellevue Group first reported a position in ZBH in Q1 2016 and has held it in 41 quarters since. The position peaked at $48.7M in Q2 2024. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.
- Bellevue Group held 155,571 shares of Zimmer Biomet worth $14.1M as of Q1 2026.
- Bellevue Group sold 83,109 Zimmer Biomet shares in Q1 2026, an estimated $7.63M.
- Zimmer Biomet made up 0.33% of Bellevue Group's portfolio in Q1 2026, its #57 holding.
- Bellevue Group first reported a position in Zimmer Biomet in Q1 2016 and has held it in 41 quarters since.
- Bellevue Group's Zimmer Biomet position peaked at $48.7M in Q2 2024.
- 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.